Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, open-label, dose-seeking study of AZD2171 [cediranib] given daily orally in combination with standard chemotherapy regimens (CT) in patients with advanced incurable non-small cell lung cancer (NSCLC) or colorectal cancer or other tumor types suitable for treatment with capecitabine.

Next Previous
X
Search
Trial Profile

A phase I, open-label, dose-seeking study of AZD2171 [cediranib] given daily orally in combination with standard chemotherapy regimens (CT) in patients with advanced incurable non-small cell lung cancer (NSCLC) or colorectal cancer or other tumor types suitable for treatment with capecitabine.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cediranib (Primary) ; Capecitabine; Carboplatin; Paclitaxel
  • Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 18 Jan 2011 Actual End Date (1 Jan 2011) added as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2010 Planned end date changed from 1 Jun 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top